Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by VentureBrotheron Mar 02, 2021 9:08am
253 Views
Post# 32693350

Here is a story

Here is a story

June 2020 - Feb 2021, its a mystery what happened 

Company stock is frozen on the exchange, nothing but crickets

Known only by personal introductions, never by association. A company quietly conducted their work in the shadows. 

Fast forward to Febuary, a compound R-107 is revealed to the market 

But what happened during those 7 months? 

Call it specualtion, but a hunch tells me that the news line is going active. 7 months of research.

Covid is not going away, it will become as common as the cold. Vaccines will curb, but not solve. Other strains have arised. Least not forget the high potential for covid to mutate with influenza. 

Ask yourself, what will happen when this stock enters a FDA / HA clinical trail?

<< Previous
Bullboard Posts
Next >>